Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study

Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey, Haifa Kathrin Al-Ali, Renato Tavares, Margherita Maffioli, Pia Raanani, Pilar Giraldo, Martin Griesshammer, Paola Guglielmelli, Catherine Bouard, Carole Paley, Ranjan Tiwari, Alessandro M. Vannucchi

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study'. Together they form a unique fingerprint.

Medicine & Life Sciences